Physician profile
John E Vargas
NPI 1063692044
$19,119.08
in general payments reported to CMS, 2019-2025
49 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,852 · 2020: $2,117 · 2021: $3,459 · 2022: $2,655 · 2023: $2,590 · 2024: $2,947 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,023 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,023.07 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,340.58 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $1,443.10 | 2019-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,418.42 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $1,221.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,202.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Grifols USA, LLC | $1,033.11 | 2019-2025 | Prolastin-C Liquid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $789.14 | 2021-2024 | Caplyta |
| Sumitomo Pharma America, INC. | $694.10 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $651.39 | 2019-2022 | |
| Amgen INC. | $611.08 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $581.72 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $580.55 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $552.17 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $534.58 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $514.77 | 2019-2025 | Airsupra, Breztri, Farxiga |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.